The biggest manager of prescription drug benefits in the US said that it is going to cover a $1-a-capsule substitute for Daraprim, an anti-parasitic treatment costing $750 per pill, following a hike in the price of the drug by Turing Pharmaceuticals AG from $13.50 this year.

In a statement, Express Scripts Holding Co. said it is going to collaborate with Imprimis Pharmaceuticals Inc., which is a San Diego-based company specialized in compounded drugs.

Imprimis began making a medicine as cheap as $1 per capsule in October. The capsule contains the active ingredient in Daraprim, pyrimethamine, along with a vitamin known as leucovorin that Daraprim is generally taken with.

The price hike for Daraprim, a decades-old drug that doesn’t enjoy patent protection any longer, drew anger from doctors, politicians and health insurers. As a compounding pharmacy is going to combine the two drugs, Express Scripts doesn’t require waiting for an FDA-approved direct competitor to Daraprim for hitting the market at a lower cost.

In an interview on Monday, Steve Miller, chief medical officer for Express Scripts, said that the $750-a-pill price was not at all acceptable. Use of a compounded drug is easy, elegant solution that would help desperate patients get the drugs they need at a reasonable rate. Miller added that as Daraprim isn’t required in huge quantities, Imprimis must not face a supply problem.

Daraprim is a treatment for a condition known as toxoplasmosis, which builds by a parasite that can become active in people, who have weakened immune systems due to HIV, chemotherapy or other treatments or conditions.